Vanguard Investments Australia
BBIO icon

Vanguard Investments Australia’s BridgeBio Pharma BBIO Stock Holding History

Vanguard Investments Australia’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.73M Hold
36,591
– – 0.01% 794
2026
Q1 		$2.72M Buy
+36,591
New +$2.65M 0.01% 757

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Vanguard Investments Australia's BBIO Position: Q2 2026 in Review

Vanguard Investments Australia held its BridgeBio Pharma (BBIO) position steady in Q2 2026 at 36,591 shares worth $2.73M. The position accounts for 0.01% of the portfolio, ranked #794.

Vanguard Investments Australia first reported a position in BBIO in Q1 2026 and has held it in 2 quarters since. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • Vanguard Investments Australia held 36,591 shares of BridgeBio Pharma worth $2.73M as of Q2 2026.
  • Vanguard Investments Australia left its BridgeBio Pharma share count unchanged in Q2 2026.
  • BridgeBio Pharma made up 0.01% of Vanguard Investments Australia's portfolio in Q2 2026, its #794 holding.
  • Vanguard Investments Australia first reported a position in BridgeBio Pharma in Q1 2026 and has held it in 2 quarters since.
  • 474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Vanguard Investments Australia's 13F filing for Q2 2026, filed 13 Aug 2026.